ARCT-021 single dose priming + ARCT-021 two lower dose priming + ARCT-021 two higher dose priming + Placebo (two doses), priming + Randomized booster + Placebo booster
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19, SARS-CoV Infection, Corona Virus Infection
Trial Timeline
Jan 7, 2021 → Mar 1, 2022
NCT ID
NCT04668339About ARCT-021 single dose priming + ARCT-021 two lower dose priming + ARCT-021 two higher dose priming + Placebo (two doses), priming + Randomized booster + Placebo booster
ARCT-021 single dose priming + ARCT-021 two lower dose priming + ARCT-021 two higher dose priming + Placebo (two doses), priming + Randomized booster + Placebo booster is a phase 2 stage product being developed by Arcturus Therapeutics for Covid19. The current trial status is terminated. This product is registered under clinical trial identifier NCT04668339. Target conditions include Covid19, SARS-CoV Infection, Corona Virus Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04668339 | Phase 2 | Terminated |
Competing Products
20 competing products in Covid19